Skip to main content
Fig. 5 | Arthritis Research & Therapy

Fig. 5

From: Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study

Fig. 5

Average pain in the index joint responders. The proportion of patients achieving ≥30% (A), ≥50% (B), ≥70% (C), or ≥90% (D) reductions from baseline in average pain in the index joint at weeks 2, 4, 8, 16, and 56 is shown. Proportions shown above each bar are rounded to the nearest percent. *Unadjusted p ≤ 0.05 versus NSAID. NSAID, nonsteroidal anti-inflammatory drug

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us